Pages that link to "Q33627135"

The following pages link to A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors (Q33627135):

Displaying 26 items.

• Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer (Q28247712) (← links)
• PolyADP-Ribosylation Is Required for Pronuclear Fusion during Postfertilization in Mice (Q33686878) (← links)
• Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancer (Q34017668) (← links)
• A phenanthrene derived PARP inhibitor is an extra-centrosomes de-clustering agent exclusively eradicating human cancer cells (Q34029054) (← links)
• Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition (Q34516867) (← links)
• The PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest (Q35255891) (← links)
• Therapeutic advances in women's cancers (Q35418973) (← links)
• Poly(ADP-ribose) polymerase as a novel regulator of 17β-estradiol-induced cell growth through a control of the estrogen receptor/IGF-1 receptor/PDZK1 axis (Q35857399) (← links)
• Polymorphisms in poly (ADP-ribose) polymerase-1 (PARP1) promoter and 3' untranslated region and their association with PARP1 expression in breast cancer patients (Q35919277) (← links)
• Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress (Q36191522) (← links)
• CDK2-dependent activation of PARP-1 is required for hormonal gene regulation in breast cancer cells. (Q36213722) (← links)
• Erythropoietin-driven signalling and cell migration mediated by polyADP-ribosylation (Q36387871) (← links)
• Cell death associated with abnormal mitosis observed by confocal imaging in live cancer cells. (Q37376022) (← links)
• The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets (Q37770152) (← links)
• PARP inhibitors--current status and the walk towards early breast cancer (Q37947887) (← links)
• Quantitative multi-parametric evaluation of centrosome declustering drugs: centrosome amplification, mitotic phenotype, cell cycle and death (Q38999741) (← links)
• Inhibition of poly(ADP-ribose) polymerase (PARP) induces apoptosis in lung cancer cell lines (Q39455969) (← links)
• PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy (Q39575484) (← links)
• PARP Inhibition Suppresses Growth of EGFR-Mutant Cancers by Targeting Nuclear PKM2 (Q39791288) (← links)
• Exclusive destruction of mitotic spindles in human cancer cells (Q42290806) (← links)
• Novel insights into the neuroendocrine control of inflammation: the role of GR and PARP1. (Q42781123) (← links)
• PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2? (Q42924589) (← links)
• RBR-type E3 ubiquitin ligase RNF144A targets PARP1 for ubiquitin-dependent degradation and regulates PARP inhibitor sensitivity in breast cancer cells (Q47156447) (← links)
• Vascular endothelial growth factor confers endothelial resistance to apoptosis through poly(ADP-ribose) polymerase (Q50277380) (← links)
• Apigenin, a dietary flavonoid, induces apoptosis, DNA damage, and oxidative stress in human breast cancer MCF-7 and MDA MB-231 cells. (Q51733786) (← links)
• Signal-induced PARP1-Erk synergism mediates IEG expression (Q64052985) (← links)